These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33176798)

  • 1. Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases.
    Hamesch K; Guldiken N; Aly M; Hüser N; Hartmann D; Rufat P; Ziol M; Remih K; Lurje G; Scheiner B; Trautwein C; Mandorfer M; Reiberger T; Mueller S; Bruns T; Nahon P; Strnad P
    BMC Med; 2020 Nov; 18(1):336. PubMed ID: 33176798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum keratin 19 (CYFRA21-1) is a prognostic biomarker in severe alcoholic hepatitis.
    Atkinson SR; Aly M; Remih K; Tyson LD; Guldiken N; Goldin R; Quaglia A; Thursz M; Strnad P
    Liver Int; 2022 May; 42(5):1049-1057. PubMed ID: 35220651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease.
    Guldiken N; Kobazi Ensari G; Lahiri P; Couchy G; Preisinger C; Liedtke C; Zimmermann HW; Ziol M; Boor P; Zucman-Rossi J; Trautwein C; Strnad P
    J Hepatol; 2016 Sep; 65(3):552-9. PubMed ID: 27151178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
    Costa D; Simbrunner B; Jachs M; Hartl L; Bauer D; Paternostro R; Schwabl P; Scheiner B; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
    J Hepatol; 2021 Apr; 74(4):819-828. PubMed ID: 33075344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient ≤ 10 mm Hg.
    Jindal A; Sarin SK; Kumar M; Kumar G
    Dig Dis Sci; 2022 Nov; 67(11):5280-5289. PubMed ID: 35113276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity.
    Zhong B; Strnad P; Selmi C; Invernizzi P; Tao GZ; Caleffi A; Chen M; Bianchi I; Podda M; Pietrangelo A; Gershwin ME; Omary MB
    Hepatology; 2009 Aug; 50(2):546-54. PubMed ID: 19585610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis.
    Cho EJ; Kim MY; Lee JH; Lee IY; Lim YL; Choi DH; Kim YJ; Yoon JH; Baik SK
    PLoS One; 2015; 10(7):e0133935. PubMed ID: 26196942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.
    Simbrunner B; Marculescu R; Scheiner B; Schwabl P; Bucsics T; Stadlmann A; Bauer DJM; Paternostro R; Eigenbauer E; Pinter M; Stättermayer AF; Trauner M; Mandorfer M; Reiberger T
    Liver Int; 2020 Jul; 40(7):1713-1724. PubMed ID: 32358998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
    Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
    World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.
    Simbrunner B; Stadlmann A; Schwabl P; Paternostro R; Bauer DJM; Bucsics T; Scheiner B; Lampichler K; Wöran K; Beer A; Eigenbauer E; Pinter M; Stättermayer AF; Marculescu R; Szekeres T; Trauner M; Mandorfer M; Reiberger T
    Dig Liver Dis; 2021 Mar; 53(3):345-352. PubMed ID: 33032973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of keratin 19 favours the development of cholestatic liver disease through decreased ductular reaction.
    Chen Y; Guldiken N; Spurny M; Mohammed HH; Haybaeck J; Pollheimer MJ; Fickert P; Gassler N; Jeon MK; Trautwein C; Strnad P
    J Pathol; 2015 Nov; 237(3):343-54. PubMed ID: 26108453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis.
    Rodrigues SG; Montani M; Guixé-Muntet S; De Gottardi A; Berzigotti A; Bosch J
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2101-2109.e1. PubMed ID: 30625404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver.
    Ku NO; Strnad P; Bantel H; Omary MB
    Hepatology; 2016 Sep; 64(3):966-76. PubMed ID: 26853542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease.
    Balcar L; Krawanja J; Scheiner B; Paternostro R; Simbrunner B; Semmler G; Jachs M; Hartl L; Stättermayer AF; Schwabl P; Pinter M; Szekeres T; Trauner M; Reiberger T; Mandorfer M
    JHEP Rep; 2023 Apr; 5(4):100682. PubMed ID: 36873421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis.
    Simbrunner B; Semmler G; Stadlmann A; Scheiner B; Schwabl P; Paternostro R; Bucsics T; Bauer D; Eigenbauer E; Pinter M; Stättermayer AF; Quehenberger P; Marculescu R; Trauner M; Mandorfer M; Reiberger T
    Hepatol Int; 2020 Dec; 14(6):1093-1103. PubMed ID: 33289910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension.
    Paternostro R; Bardach C; Hofer BS; Scheiner B; Schwabl P; Asenbaum U; Ba-Ssalamah A; Scharitzer M; Bucscis T; Simbrunner B; Bauer D; Trauner M; Mandorfer M; Reiberger T; Lampichler K
    Liver Int; 2021 Apr; 41(4):799-809. PubMed ID: 33290614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome.
    Simbrunner B; Villesen IF; Scheiner B; Paternostro R; Schwabl P; Stättermayer AF; Marculescu R; Pinter M; Quehenberger P; Trauner M; Karsdal M; Lisman T; Reiberger T; Leeming DJ; Mandorfer M
    Hepatol Int; 2023 Dec; 17(6):1532-1544. PubMed ID: 37605068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Evaluation and Prognosis.
    Hernández-Gea V; Berzigotti A
    Dig Dis; 2015; 33(4):515-23. PubMed ID: 26159268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum keratin-18 fragments as cell death biomarker in association with disease progression and prognosis in hepatitis B virus-related cirrhosis.
    Cao Z; Chen L; Li J; Liu Y; Bao R; Liu K; Yan L; Ding Y; Guo Q; Xiang X; Xie J; Lin L; Xie Q; Bao S; Wang H
    J Viral Hepat; 2019 Jul; 26(7):835-845. PubMed ID: 30974482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.